Latest Regenerative Medicine News

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.